FY2024 Earnings Estimate for Edwards Lifesciences Co. (NYSE:EW) Issued By Zacks Research

Edwards Lifesciences Co. (NYSE:EW) – Zacks Research dropped their FY2024 EPS estimates for shares of Edwards Lifesciences in a report released on Wednesday, August 14th. Zacks Research analyst U. Biswas now forecasts that the medical research company will post earnings per share of $2.68 for the year, down from their previous forecast of $2.77. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.71 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q3 2025 earnings at $0.70 EPS, Q4 2025 earnings at $0.69 EPS and FY2025 earnings at $2.78 EPS.

A number of other research analysts also recently issued reports on EW. Royal Bank of Canada decreased their price target on shares of Edwards Lifesciences from $101.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, July 25th. TD Cowen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $100.00 to $70.00 in a research note on Thursday, July 25th. The Goldman Sachs Group cut their price target on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. JPMorgan Chase & Co. cut Edwards Lifesciences from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $105.00 to $72.00 in a research report on Thursday, July 25th. Finally, Piper Sandler dropped their price objective on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a report on Thursday, July 25th. Fourteen analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $82.10.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $69.36 on Monday. The business has a 50-day simple moving average of $80.05 and a 200-day simple moving average of $85.70. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The company has a market cap of $41.80 billion, a PE ratio of 29.90, a P/E/G ratio of 2.57 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same period last year, the business posted $0.66 earnings per share. Edwards Lifesciences’s revenue was up 6.7% compared to the same quarter last year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,101,530.88. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,867 shares of company stock worth $2,077,526. 1.29% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently bought and sold shares of EW. International Assets Investment Management LLC grew its holdings in shares of Edwards Lifesciences by 9,720.7% in the 4th quarter. International Assets Investment Management LLC now owns 106,064 shares of the medical research company’s stock worth $8,087,000 after acquiring an additional 104,984 shares during the period. SVB Wealth LLC grew its holdings in Edwards Lifesciences by 23.4% in the fourth quarter. SVB Wealth LLC now owns 6,059 shares of the medical research company’s stock valued at $462,000 after purchasing an additional 1,150 shares during the last quarter. abrdn plc increased its position in shares of Edwards Lifesciences by 130.2% in the fourth quarter. abrdn plc now owns 1,305,854 shares of the medical research company’s stock valued at $99,571,000 after buying an additional 738,648 shares in the last quarter. Lindbrook Capital LLC raised its stake in shares of Edwards Lifesciences by 6.8% during the 4th quarter. Lindbrook Capital LLC now owns 3,830 shares of the medical research company’s stock worth $292,000 after buying an additional 245 shares during the last quarter. Finally, Verdence Capital Advisors LLC boosted its position in shares of Edwards Lifesciences by 16.2% in the 4th quarter. Verdence Capital Advisors LLC now owns 10,830 shares of the medical research company’s stock worth $826,000 after buying an additional 1,509 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.